We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
1
Agios Pharmaceuticals
AGIO
$1.79B
$131M 2.87%
2,543,600
+20,079
+0.8% +$994K
HUM icon
2
Humana
HUM
$43.7B
$126M 2.75%
301,000
+16,000
+6% +$6.39M
ZLAB icon
3
Zai Lab
ZLAB
$2.06B
$125M 2.72%
933,500
+78,601
+9% +$12.2M
AVIR icon
4
Atea Pharmaceuticals
AVIR
$376M
$105M 2.28%
1,694,903
-2,500
-0.1% -$169K
UNH icon
5
UnitedHealth
UNH
$376B
$102M 2.23%
275,000
-130,000
-32% -$45M
FPRX
6
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$100M 2.19%
2,660,822
+1,939,189
+269% +$48.4M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.8B
$98.7M 2.15%
1,015,000
-560,000
-36% -$58.7M
IMCR icon
8
Immunocore
IMCR
$1.72B
$97.6M 2.13%
+2,292,285
New +$102M
PODD icon
9
Insulet
PODD
$11.5B
$96.8M 2.11%
371,000
+53,000
+17% +$14.2M
ALGN icon
10
Align Technology
ALGN
$12.1B
$96.1M 2.1%
177,500
+14,000
+9% +$7.74M
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$89.9M 1.96%
3,569,192
+893,092
+33% +$17.5M
ISRG icon
12
Intuitive Surgical
ISRG
$127B
$88.7M 1.93%
360,000
– –
IDXX icon
13
Idexx Laboratories
IDXX
$44.1B
$88.1M 1.92%
180,000
+55,000
+44% +$27.6M
HCA icon
14
HCA Healthcare
HCA
$87.2B
$84.8M 1.85%
450,000
– –
NVTA
15
DELISTED
Invitae Corporation
NVTA
$84.6M 1.85%
2,213,977
+361,910
+20% +$16.5M
NVAX icon
16
Novavax
NVAX
$1.2B
$83.6M 1.82%
461,000
-102,205
-18% -$20.4M
ARGX icon
17
argenx
ARGX
$53.4B
$82.6M 1.8%
300,000
+12,500
+4% +$3.95M
FRPT icon
18
Freshpet
FRPT
$2.93B
$80.4M 1.75%
506,500
– –
EXAS
19
DELISTED
Exact Sciences
EXAS
$75.1M 1.64%
570,000
+85,000
+18% +$11.6M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$72.6M 1.58%
746,732
-95,268
-11% -$9.51M
PCRX icon
21
Pacira BioSciences
PCRX
$1.04B
$71.8M 1.57%
1,025,000
– –
ONC
22
BeOne Medicines Ltd
ONC
$32.8B
$69.6M 1.52%
200,000
-25,000
-11% -$8.28M
NVRO
23
DELISTED
NEVRO CORP.
NVRO
$67.7M 1.48%
485,000
+90,000
+23% +$14.7M
IRTC icon
24
iRhythm Holdings
IRTC
$3.85B
$60.1M 1.31%
432,496
-192,504
-31% -$34.5M
HZNP
25
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$57.5M 1.26%
625,000
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.